Levetiracetam versus Clobazam for prophylaxis of febrile seizures

Levetiracetam versus Clobazam for prophylaxis of febrile seizures in children

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210911052441N1

Enrollment

Registered

2025-06-23

Start date

2021-02-19

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Febrile convulsion. Febrile convulsions

Interventions

Intervention 1: Intervention group: Levetiracetam: Levetiracetam syrup 30mg/Kg per dose, used for 48 hours after the onset of fever. This syrup is drawn up with a syringe according to the dose and giv

Eligibility

Sex/Gender

All

Age

6 Months to 6 Years

Inclusion criteria

Inclusion criteria: Children with febrile seizures

Exclusion criteria

Exclusion criteria: Neurologic disease Metabolic disorder epilepsy trauma meningitis

Design outcomes

Primary

Measure	Time frame
Number of febrile seizure recurrences in treated children. Timepoint: One year later. Method of measurement: Oral questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Zamanian

Kashan University of Medical Sciences

zamanyan-f@kaums.ac.ir+98-31-55540026-31

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026